Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics

Eton Pharmaceuticals, Inc. (ETON)

Today's Latest Price: $8.16 USD

0.08 (0.99%)

Updated Dec 4 4:00pm

Add ETON to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ETON Stock Summary

  • ETON's went public 2.06 years ago, making it older than just 4.52% of listed US stocks we're tracking.
  • ETON's price/sales ratio is 468.01; that's higher than the P/S ratio of 98.83% of US stocks.
  • With a year-over-year growth in debt of 13,375%, Eton Pharmaceuticals Inc's debt growth rate surpasses 99.6% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Eton Pharmaceuticals Inc, a group of peers worth examining would be RVNC, VBIV, SNDX, SAGE, and RETA.
  • Visit ETON's SEC page to see the company's official filings. To visit the company's web site, go to

ETON Stock Price Chart Interactive Chart >

Price chart for ETON

ETON Price/Volume Stats

Current price $8.16 52-week high $9.12
Prev. close $8.08 52-week low $2.50
Day low $8.00 Volume 185,100
Day high $8.31 Avg. volume 256,514
50-day MA $7.47 Dividend yield N/A
200-day MA $6.04 Market Cap 197.59M

Eton Pharmaceuticals, Inc. (ETON) Company Bio

Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.

ETON Latest News Stream

Event/Time News Detail
Loading, please wait...

ETON Latest Social Stream

Loading social stream, please wait...

View Full ETON Social Stream

Latest ETON News From Around the Web

Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.

FDA OKs Eton Pharma's hydrocortisone as replacement therapy in pediatric adrenocortical insufficiency

The FDA has approved Eton Pharmaceuticals' (ETON) ALKINDI SPRINKLE (hydrocortisone) oral granules as replacement therapy for Adrenocortical Insufficiency ((AI)) in children under 17 years of age.Pediatric AI is a rare disease characterized by an inability to synthesize and release cortisol and aldosterone, causing abnormal sexual development in females, premature puberty, premature...

Seeking Alpha | September 30, 2020

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

September proved to be a mixed month as far as drug approvals are concerned, with Mallinckrodt PLC (NYSE: MNK ) and Aquestive Therapeutics Inc (NASDAQ: AQST ) facing rejections. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Among the more fortunate ones were GlaxoSmithKline plc (NYSE: GSK ), which got the nod for an expanded indication - hypereosinophilic syndrome. Bristol-Myers Squibb Co's (NYSE: BMY ) leukemia drug also received FDA's blessings, and after several hiccups, Eton Pharmaceuticals Inc's (NASDAQ: ETON ) out-licensed preservative-free allergic conjunctivitis ophthalmic...

Benzinga | September 30, 2020

FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%

LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA)…

PR Newswire | September 25, 2020

The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, Biotech IPOs

Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) and Fennec Pharmaceuticals Inc (NASDAQ: FENC ) received complete response letters for their respective regulatory applications, while a decision on Eton Pharmaceuticals Inc's (NASDAQ: ETON ) eye inflammation drug hadn't come by the Aug. 10 decision date. The week, however, saw a signing spree by coronavirus vaccine developers, which stitched up manufacturing as well as supply deals. Here are the key catalysts for the unfolding week. Conferences Virtual Keystone Symposia: Advances in Cancer Immunotherapy: Aug. 17-19 PDUFA Dates Gilead Sciences, Inc. (NASDAQ: GILD ) and lic...

Benzinga | August 16, 2020

Eton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q2 2020 Results - Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants David Krempa – Vice President of Business Development Sean Brynjelsen – Chief Executive Officer Paul Stickler – Senior Vice President of Sales and Marketing Wilson Troutman – Chief Financial Officer Conference Call Participants...

SA Transcripts on Seeking Alpha | August 13, 2020

Read More 'ETON' Stories Here

ETON Price Returns

1-mo 15.09%
3-mo 12.40%
6-mo 50.55%
1-year 36.45%
3-year N/A
5-year N/A
YTD 13.33%
2019 17.65%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8273 seconds.